Idorsia submits NDA for clazosentan to Japanese PMDA

Idorsia announces financial results for 2020 – a successful year marked by outstanding clinical data

Idorsia reports results in relation to the Axovan arbitration – claim dismissed by Arbitral Tribunal

Idorsia to debut at the 39th J.P. Morgan Healthcare Conference – Major catalysts expected in the near-term – Daridorexant NDA submitted to the US FDA

Idorsia announces positive results of the two Japanese registration studies with clazosentan

Idorsia announces financial results for the first nine months of 2020

Idorsia successfully completes capital increase with gross proceeds of CHF 535.5 million

Idorsia announces the results of its rights offering in the context of the capital increase

Idorsia announces capital increase to prepare for the launch of daridorexant and further fund its diversified pipeline

Janssen announces the presentation of additional ponesimod data at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting

Idorsia assigns and transfers agreement with ReveraGen to Santhera

Idorsia selects Syneos Health as commercialization partner to launch daridorexant in the United States

Daridorexant Phase 3 results in insomnia presented at SLEEP 2020

Daridorexant Phase 3 results in insomnia to be presented at SLEEP 2020

Idorsia Japan confirms daridorexant dose response in Japanese patients with insomnia – preparation for a local registration program advancing

Idorsia announces financial results for the first half 2020

Idorsia establishes US commercial operations and leadership team

Idorsia announces positive results in the second Phase 3 study of daridorexant

Idorsia successfully completes the offering of new shares thereby securing funding for the company’s growth plan

Idorsia launches an offering of new shares to fund the company’s growth plan